Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of “Hold” by Brokerages

Atossa Genetics Inc. (NASDAQ:ATOS) has been given a consensus rating of “Hold” by the five brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $36.3333.

A number of research firms have weighed in on ATOS. Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a report on Monday, April 20th. HC Wainwright increased their target price on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Finally, Ascendiant Capital Markets reduced their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, April 10th.

Atossa Genetics Stock Down 0.7%

ATOS stock opened at $5.33 on Friday. The business has a 50 day moving average price of $5.09 and a 200 day moving average price of $8.53. The stock has a market cap of $45.89 million, a price-to-earnings ratio of -1.48 and a beta of 1.25. Atossa Genetics has a fifty-two week low of $3.76 and a fifty-two week high of $19.35.

Institutional Trading of Atossa Genetics

Institutional investors and hedge funds have recently made changes to their positions in the company. &PARTNERS acquired a new stake in shares of Atossa Genetics in the 4th quarter valued at about $25,000. Hudson Bay Capital Management LP acquired a new position in Atossa Genetics during the second quarter worth approximately $26,000. Gallagher Capital Advisors LLC acquired a new position in Atossa Genetics during the third quarter worth approximately $27,000. JPMorgan Chase & Co. lifted its stake in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after buying an additional 35,474 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.